In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
Under the terms of the deal, the pharmaceutical giant will pay Gubra ... to tamp down appetite and regulate blood sugar, while Eli Lilly's own drug Zepbound targets both GLP-1 and another hormone ...
With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback